Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

BACKGROUND: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG + F/TAF)....

Descripción completa

Detalles Bibliográficos
Autores principales: Sax, Paul E., Arribas, José R., Orkin, Chloe, Lazzarin, Adriano, Pozniak, Anton, DeJesus, Edwin, Maggiolo, Franco, Stellbrink, Hans-Jürgen, Yazdanpanah, Yazdan, Acosta, Rima, Huang, Hailin, Hindman, Jason T., Martin, Hal, Baeten, Jared M., Wohl, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186485/
https://www.ncbi.nlm.nih.gov/pubmed/37200995
http://dx.doi.org/10.1016/j.eclinm.2023.101991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186485/
https://www.ncbi.nlm.nih.gov/pubmed/37200995
http://dx.doi.org/10.1016/j.eclinm.2023.101991

Ejemplares similares